The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.
Florian Lordick
No relevant relationships to disclose
Yoon-Koo Kang
Consultant or Advisory Role - Merck KGaA; Novartis; Roche; Sanofi
Honoraria - Novartis; Roche (B); Sanofi
Research Funding - Bayer; Novartis
Pamela Salman
No relevant relationships to disclose
Sang Cheul Oh
No relevant relationships to disclose
Gyorgy Bodoky
Consultant or Advisory Role - Amgen
Galina Petrova Kurteva
No relevant relationships to disclose
Constantin D. Volovat
No relevant relationships to disclose
Vladimir Moiseyenko
No relevant relationships to disclose
Akira Sawaki
No relevant relationships to disclose
Joon Oh Park
No relevant relationships to disclose
Vera A. Gorbunova
No relevant relationships to disclose
Heiko Goette
Employment or Leadership Position - Merck KGaA
Helena Melezinkova
Employment or Leadership Position - Merck Serono (B)
Christopher Stroh
Employment or Leadership Position - Merck KGaA
Markus Moehler
Consultant or Advisory Role - Amgen; Medac; Merck KGaA; Roche
Honoraria - Medac; Merck KGaA; Roche
Other Remuneration - Amgen; Merck KGaA; Roche